MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ
19.85
+1.30
+7.01%
After Hours: 19.80 -0.05 -0.25% 19:41 12/19 EST
OPEN
18.76
PREV CLOSE
18.55
HIGH
20.11
LOW
18.73
VOLUME
4.12M
TURNOVER
--
52 WEEK HIGH
26.69
52 WEEK LOW
6.36
MARKET CAP
3.21B
P/E (TTM)
-5.4198
1D
5D
1M
3M
1Y
5Y
1D
What Dyne Therapeutics (DYN)'s DELIVER Data and $350 Million Raise Mean For Shareholders
Simply Wall St · 38m ago
50 heavily shorted laggards poised to rebound according to Wells Fargo
Seeking Alpha · 3d ago
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings
Seeking Alpha · 3d ago
Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus
TipRanks · 4d ago
Dyne Therapeutics Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 4d ago
Dyne Therapeutics Price Target Cut to $36.00/Share From $38.00 by Evercore ISI Group
Dow Jones · 4d ago
Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $36
Benzinga · 4d ago
Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI
TipRanks · 4d ago
More
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.

Webull offers Dyne Therapeutics Inc stock information, including NASDAQ: DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.